<DOC>
	<DOCNO>NCT00818324</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy OPC-12759 ophthalmic suspension 52 week dry eye patient</brief_summary>
	<brief_title>Long Term Administration Study OPC-12759 Ophthalmic Suspension</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>1 . Out patient ; 2 . Ocular discomfort severity moderate severe ; 3 . Cornealconjunctival damage moderate severe ; 4 . Unanesthetized Schirmer 's test score 5mm/5minutes less , tear breakup time 5 second less ; 5 . Best correct visual acuity 0.2 good eye . 1 . Presence anterior segment disease disorder associate keratoconjunctivitis scicca ; 2 . Ocular hypertention patient glaucoma patient ophthalmic solution ; 3 . Anticipated use topicallyinstilled ocular medication patient discontinue use study ; 4 . Anticipated use contact lens study ; 5 . Patient punctal plug ; 6 . Any history ocular surgery within 12 month ; 7 . Female patient pregnant , possibly pregnant breast feeding ; 8 . Known hypersensitivity component study drug procedual medication ; 9 . Receipt investigational product within 4 month .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>